Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40; New Analgesic Products Make It Past US FDA
Executive Summary
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Intravenous Tramadol CRL Casts Shadow On Avenue’s Cipla Deal
Avenue’s two-stage deal with an arm of Cipla faces uncertainty following a US Complete Response Letter for its intravenous tramadol. The US firm says it is "very surprised" with the potential safety concern raised and plans to seek a meeting with the agency at the earliest to resolve the issue.
Intravenous Tramadol CRL Casts Shadow On Avenue’s Cipla Deal
Avenue’s two-stage deal with an arm of Cipla faces uncertainty following a US Complete Response Letter for its intravenous tramadol. The US firm says it is "very surprised" with the potential safety concern raised and plans to seek a meeting with the agency at the earliest to resolve the issue.
Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: